lilly retatrutide trial Lilly's triple agonist achieves 16.8% weight loss in phase 3 Lilly's 'triple G' agonist triumphs

Dual GLP1 and GIP agonists Tirzepatide is a once weekly, subcutaneous, unimolecular dual RA (GLP-1 and GIP) which has comparable GIP receptor binding affinity to native GIP and 5 times lower GLP-1 receptor affinity than that of native GLP-1

Side Effects: What to Expect The most common side effects of GLP-1 medications are gastrointestinal symptoms, including nausea, vomiting, diarrhea, constipation, indigestion, and abdominal discomfort

These medications help level the playing field, giving people a tool to push back

Bibcode:2005FEBSL.579..803M

Mounjaro (Injection) Indication : Type 2 Diabetes Frequency : Weekly Zepbound (Injection) Indication : Chronic weight management Frequency : Weekly 3